Incyte Corporation (INCY)

Market Cap	20.51B
Revenue (ttm)	4.81B
Net Income (ttm)	1.19B
Shares Out	196.32M
EPS (ttm)	5.90
PE Ratio	17.70
Forward PE	13.76
Dividend	n/a
Ex-Dividend Date	n/a

Volume	932,388
Open	106.45
Previous Close	105.65
Day's Range	103.85 - 106.99
52-Week Range	53.56 - 109.28
Beta	0.83
Analysts	Buy
Price Target	90.71 (-13.16%)
Earnings Date	Oct 28, 2025

About INCY

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 4, 1993
• Employees: 2,617
• Stock Exchange: NASDAQ
• Ticker Symbol: INCY
• Website: https://www.incyte.com

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.

Analyst Summary

According to 20 analysts, the average rating for INCY stock is "Buy." The 12-month stock price target is $90.71, which is a decrease of -13.16% from the latest price.

Price Target

$90.71

(-13.16% downside)

Analyst Consensus: Buy